Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: M-M-RVAXPRO   
Auth. number : EU/1/06/337
INN : Measles, Mumps and Rubella Vaccine (Live)
ATC: Anatomical main group: J - General antiinfectives for systemic use
Therapeutic subgroup: J07 - Vaccines
Pharmacological subgroup: J07B - Viral vaccines
Chemical subgroup: J07BD - Measles vaccines
Chemical substance: J07BD52 - Measles, combinations with mumps and rubella, live attenuated
(See WHO ATC Index)
Indication: M-M-RVAXPRO is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older
Marketing Authorisation Holder: Sanofi Pasteur MSD, SNC
8 rue Jonas Salk, F-69007 Lyon, France

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/05/2006 Centralised - Authorisation EMEA/H/C/604 (2006)1959 of 05/05/2006
01/01/2007 Centralised - Variation EMEA/H/C/604/IB/4
30/01/2007 Centralised - Variation EMEA/H/C/604/N/3
Updated with Decision(2007)1885 of 23/04/2007
25/04/2007 Centralised - Variation EMEA/H/C/604/II/5 (2007)1885 of 23/04/2007
22/05/2007 Centralised - Variation EMEA/H/C/604/IA/7
27/06/2007 Centralised - Variation EMEA/H/C/604/II/6 (2007)3181 of 25/06/2007
25/09/2007 Centralised - Variation EMEA/H/C/604/II/8
23/01/2008 Centralised - Variation EMEA/H/C/604/IA/10
23/04/2008 Centralised - Variation EMEA/H/C/604/II/12 (2008)1635 of 18/04/2008
24/06/2008 Centralised - Variation EMEA/H/C/604/II/11 (2008)3205 of 20/06/2008
27/03/2009 Centralised - Variation EMEA/H/C/604/IA/16
30/03/2009 Centralised - Variation EMEA/H/C/604/IA/16
09/06/2009 Centralised - Variation EMEA/H/C/604/IA/17
05/01/2010 Centralised - Variation EMEA/H/C/604/II/19
21/01/2010 Centralised - Variation EMEA/H/C/604/II/20 (2010)343 of 19/01/2010
17/03/2010 Centralised - Variation EMEA/H/C/604/II/21 (2010)1808 of 15/03/2010
23/03/2010 Centralised - Variation EMEA/H/C/604/II/22
06/04/2010 Centralised - Variation EMEA/H/C/604/IA/23/G
Updated with Decision(2010)6241 of 06/09/2010
11/05/2010 Centralised - Variation EMEA/H/C/604/IA/25
22/07/2010 Centralised - Variation EMEA/H/C/604/WS/18
02/09/2010 Centralised - Variation EMEA/H/C/604/IB/26
09/09/2010 Centralised - Variation EMEA/H/C/604/II/24 (2010)6241 of 06/09/2010
28/09/2010 Centralised - Variation EMEA/H/C/604/WS/19/G
27/10/2010 Centralised - Variation EMEA/H/C/604/WS/44 (2010)7544 of 25/10/2010
17/12/2010 Centralised - Variation EMEA/H/C/604/IB/28/G
09/05/2011 Centralised - Renewal EMEA/H/C/604/R/27 (2011)3175 of 05/05/2011
16/04/2012 Centralised - Variation EMEA/H/C/604/N/43
Updated with Decision(2013)1095 of 20/02/2013
22/02/2013 Referral EMEA/H/C/604/A-20/45 (2013)1095 of 20/02/2013
01/07/2013 Centralised - Variation EMEA/H/C/604/N/52
06/05/2014 Centralised - Variation EMEA/H/C/604/IG/435